Breaking News

ABL Appoints Scientific Director

October 17, 2013

Kovacs brings extensive R&D experience

Dr. Gerald Kovacs has been appointed scientific director at ABL, Inc. Dr. Kovacs will lead the company’s scientific operations supporting U.S. government and commercial preclinical programs and oversee the continued expansion of its clinical testing capabilities.
Dr. Kovacs has more than 20 years of experience in biomedical research. Most recently he served as scientific director for the Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures at the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (HHS). While at BARDA, Dr. Kovacs directed a $5.6 billion portfolio of more than 80 vaccine and therapeutic projects spanning preclinical to Phase IV trials. In 2013, Dr. Kovacs was honored by the U.S. Department of Health and Human Services with the Secretary’s Award for Distinguished Service for obtaining FDA approval of two biodefense products. He also designed and implemented the BARDA CRO Network.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.